Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.
Stock data | 2024 | Change |
---|---|---|
Price | $0.04289551312932668 | N/A |
Market Cap | $11.05M | N/A |
Shares Outstanding | 257.60M | N/A |
Employees | 0 | N/A |